Posted by Michael Wonder on 08 Mar 2022
Vaccine approval before Phase 3 trial results: a consequence of vaccine access inequity
2 March 2022 - The final Phase 3 clinical data for CanSino Biologics' adenovirus type 5 vector vaccine show that Ad5-nCoV is efficacious.
However, emergency approval was granted in ten countries before data on its efficacy were available, even though other vaccines were already approved.
If the results of the trial had been unfavourable, millions of people would have been vaccinated and granted a false sense of protection.
